Long Ideas - Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) are rebounding from late losses on Monday, up 50% in premarket trading after the company announced an increase in the … Continue Reading
Read NowLong Ideas - Analysts and investors are refocusing on the opportunity for Pain Therapeutics’ (NASDAQ:PTIE) lead drug candidate, Remoxy. Remoxy is an extended-release formulation of the widely used … Continue Reading
Read NowLong Ideas - The Cooper Companies (NYSE:COO) handily beat estimates when it reported fiscal 3Q 2012 (F3Q) results Thursday night. Total sales for F3Q came in at $378M, … Continue Reading
Read NowLong Ideas - Orexigen Therapeutics (NASDAQ:OREX) continues this week’s gains in early trading on Thursday, up roughly 20% to $5.35 since Tuesday. The strength comes from Orexigen’s announcement … Continue Reading
Read NowLong Ideas - After announcing Wednesday morning that it has completed enrollment of its latest Phase 3 Pimavanserin trial, dubbed the -020 study, Acadia Pharmaceuticals (NASDAQ:ACAD) gained 4% … Continue Reading
Read NowLong Ideas - Nuvo Research Inc. (TSX:NRI) announced that it obtained an additional U.S. patent for Pennsaid 2%, an improved follow-on formulation of its currently marketed Pennsaid product. … Continue Reading
Read NowLong Ideas - Amarin Corp. (NASDAQ:AMRN) announced Tuesday that the U.S. Patent and Trade Office (PTO) issued a Notice of Allowance for Patent Application 13/282,145, which was based … Continue Reading
Read Now